The information below is designed to help appropriate patients get access to OPDIVO by providing helpful reimbursement information for healthcare offices. It is important that offices verify each patient’s insurance coverage prior to initiating therapy. BMS Access Support may be able to help.
Advanced Renal Cell Carcinoma
Classical Hodgkin Lymphoma
Classical Hodgkin Lymphoma (cHL) Monotherapy
Metastatic Lung Cancer
Metastatic Colorectal Cancer
Metastatic Colorectal Cancer (mCRC) Monotherapy
Metastatic Colorectal Cancer (mCRC) Combination Therapy
Metastatic Melanoma (mMelanoma) Monotherapy
Metastatic Melanoma (mMelanoma) Combination Therapy
Adjuvant Treatment of Melanoma (Adj Tx of Melanoma) Monotherapy
Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) Monotherapy
Locally Advanced or Metastatic Urothelial Carcinoma
Locally Advanced or Metastatic Urothelial Carcinoma (UC) Monotherapy
The accurate completion of reimbursement- or coverage-related documentation is the responsibility of the healthcare provider and patient. Bristol-Myers Squibb and its agents make no guarantee regarding reimbursement for any service or item.